Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981705 · ClinicalTrials.gov registry record
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- 8
- Enrollment target
NCT03981705 is a clinical trial that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 8 participants.
The verdict
NCT03981705 has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Interventions
- RADIATION Standard Trimodality Breast Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2024-11-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981705
The ClinicalTrials.gov registry entry for NCT03981705 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard Trimodality Breast Imaging is the first listed.
NCT03981705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03981705 about?
NCT03981705 is a clinical study titled "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer". This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast c...
What is the current status of trial NCT03981705?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-08-08. Estimated completion is 2024-11-26.
What interventions are being tested in trial NCT03981705?
The interventions under investigation include: Standard Trimodality Breast Imaging (RADIATION).
Who is sponsoring clinical trial NCT03981705?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.